Interventional × Mesothelioma × Dermatologic × Clear all
NCT05544929 2026-01-06

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers

Novartis

Phase 1 Active not recruiting
126 enrolled
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
NCT05238883 2025-11-21

A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

Phase 1 Active not recruiting
72 enrolled
NCT04272034 2025-10-16

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Incyte Corporation

Phase 1 Terminated
105 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
145 enrolled 47 charts
NCT04234113 2025-01-08

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Sotio Biotech Inc.

Phase 1 Terminated
115 enrolled
NCT06034860 2024-11-01

Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types

Molecular Templates, Inc.

Phase 1 Terminated
15 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT04913337 2024-10-02

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 1/2 Active not recruiting
179 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
71 enrolled
NCT04670445 2023-10-23

UPLIFT

Massachusetts General Hospital

Phase NA Unknown
210 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Incyte Corporation

Phase 1/2 Completed
52 enrolled 25 charts
NCT03071757 2022-04-28

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

AbbVie

Phase 1 Completed
139 enrolled
NCT03652077 2021-11-15

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Incyte Corporation

Phase 1 Completed
40 enrolled
NCT03538028 2020-10-30

A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies

Incyte Corporation

Phase 1 Completed
22 enrolled
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Novartis

Phase 2 Completed
185 enrolled
NCT00375245 2014-01-17

Rapamycin With Grapefruit Juice for Advanced Malignancies

University of Chicago

Phase 1 Completed
41 enrolled